Johan Bussink

List of Publications by Year
in descending order

216 papers	16,232 citations	22153 59 h-index	17592 121 g-index
220 all docs	220 docs citations	220 times ranked	21454 citing authors

#	Article	IF	Citations
1	Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications, 2014, 5, 4006.	12.8	3,355
2	Machine Learning methods for Quantitative Radiomic Biomarkers. Scientific Reports, 2015, 5, 13087.	3.3	744
3	The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. Journal of Clinical Investigation, 2010, 120, 127-141.	8.2	675
4	Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study. PLoS Medicine, 2018, 15, e1002711.	8.4	385
5	Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer. Scientific Reports, 2015, 5, 11044.	3.3	384
6	Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy. Clinical Cancer Research, 2012, 18, 5585-5594.	7.0	374
7	Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncology, The, 2008, 9, 288-296.	10.7	306
8	Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology. Frontiers in Oncology, 2016, 6, 71.	2.8	306
9	Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis. International Journal of Radiation Oncology Biology Physics, 2006, 64, 435-448.	0.8	289
10	Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Research, 2002, 62, 7066-74.	0.9	288
11	ARCON: a novel biology-based approach in radiotherapy. Lancet Oncology, The, 2002, 3, 728-737.	10.7	259
12	Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiotherapy and Oncology, 2003, 67, 3-15.	0.6	256
13	Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. Medical Physics, 2018, 45, 3449-3459.	3.0	214
14	Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Research, 2013, 15, R2.	5.0	194
15	PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4622-4627.	7.1	193
16	Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer, 2011, 11, 167.	2.6	171
17	Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiotherapy and Oncology, 2011, 99, 344-348.	0.6	161
18	Dynamics of Tumor Hypoxia Measured with Bioreductive Hypoxic Cell Markers. Radiation Research, 2007, 167, 127-145.	1.5	153

#	Article	IF	Citations
19	^{18}F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors. Journal of Nuclear Medicine, 2010, 51, 866-874.	5.0	147
20	Observer variation in target volume delineation of lung cancer related to radiation oncologist–computer interaction: A 'Big Brother' evaluation. Radiotherapy and Oncology, 2005, 77, 182-190.	0.6	145
21	18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2007, 48, 726-735.	5.0	142
22	Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiotherapy and Oncology, 2017, 123, 363-369.	0.6	136
23	The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 761-767.	1.1	134
24	Molecular aspects of tumour hypoxia. Molecular Oncology, 2008, 2, 41-53.	4.6	126
25	Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14620-14625.	7.1	121
26	Biology of Hypoxia. Seminars in Nuclear Medicine, 2015, 45, 101-109.	4.6	121
27	Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. International Journal of Radiation Oncology Biology Physics, 2002, 54, 215-228.	0.8	120
28	^{18}F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. Journal of Nuclear Medicine, 2013, 54, 532-540.	5.0	111
29	Tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of hypoxic markers. A review. Head and Neck, 2007, 29, 591-604.	2.0	107
30	Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of 18FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2014, 9, 1485-1493.	1.1	107
31	The mechanical microenvironment in cancer: How physics affects tumours. Seminars in Cancer Biology, 2015, 35, 62-70.	9.6	107
32	PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncology, The, 2010, 11, 661-669.	10.7	105
33	Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2294-2303.	6.4	104
34	Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. International Journal of Cancer, 2008, 122, 2726-2734.	5.1	104
35	^{18}F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy. Journal of Nuclear Medicine, 2013, 54, 1528-1534.	5.0	104
36	Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer, 2012, 76, 316-323.	2.0	99

#	Article	IF	Citations
37	PET of Hypoxia with ^{89}Zr-Labeled cG250-F(ab′)$_2$ in Head and Neck Tumors. Journal of Nuclear Medicine, 2010, 51, 1076-1083.	5.0	98
38	Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation. Lung Cancer, 2012, 75, 73-76.	2.0	97
39	Distributed learning on 20 000+ lung cancer patients â€" The Personal Health Train. Radiotherapy and Oncology, 2020, 144, 189-200.	0.6	97
40	Changes in tumor hypoxia measured with a double hypoxic marker technique. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1529-1538.	0.8	89
41	Clinical evidence on PETâ€"CT for radiation therapy planning in head and neck tumours. Radiotherapy and Oncology, 2010, 96, 328-334.	0.6	88
42	Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1803-1811.	6.4	85
43	The PERK/ATF4/LAMP3-arm of the unfolded protein response affects radioresistance by interfering with the DNA damage response. Radiotherapy and Oncology, 2013, 108, 415-421.	0.6	83
44	LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocrine-Related Cancer, 2014, 21, 101-112.	3.1	82
45	Hypoxic cell turnover in different solid tumor lines. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1157-1168.	0.8	79
46	Imaging Hypoxia in Xenografted and Murine Tumors With 18F-Fluoroazomycin Arabinoside: A Comparative Study Involving microPET, Autoradiography, Po2-Polarography, and Fluorescence Microscopy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1202-1212.	0.8	79
47	Clinical studies of hypoxia modification in radiotherapy. Seminars in Radiation Oncology, 2004, 14, 233-240.	2.2	75
48	PETâ€"CT for radiotherapy treatment planning and response monitoring in solid tumors. Nature Reviews Clinical Oncology, 2011, 8, 233-242.	27.6	75
49	PET in the management of locally advanced and metastatic NSCLC. Nature Reviews Clinical Oncology, 2015, 12, 395-407.	27.6	75
50	Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Research, 2011, 13, R82.	5.0	74
51	Constitutive expression of Î³-H2AX has prognostic relevance in triple negative breast cancer. Radiotherapy and Oncology, 2011, 101, 39-45.	0.6	74
52	Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET. Journal of Nuclear Medicine, 2010, 51, 66-76.	5.0	73
53	Imaging hypoxia after oxygenation-modification: Comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiotherapy and Oncology, 2006, 80, 157-164.	0.6	72
54	Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy. Seminars in Cancer Biology, 2015, 31, 99-105.	9.6	69

#	Article	IF	Citations
55	Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3397-3408.	7.0	68
56	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on ¹⁸F-FDG PET Imaging of Lung Cancer. Journal of Nuclear Medicine, 2016, 57, 1692-1698.	5.0	67
57	Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. European Radiology, 2013, 23, 748-756.	4.5	65
58	Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers. Radiotherapy and Oncology, 2013, 107, 434-441.	0.6	63
59	High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiotherapy and Oncology, 2013, 108, 440-445.	0.6	60
60	The unfolded protein response as a target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 277-284.	7.4	60
61	Dynamics of Hypoxia, Proliferation and Apoptosis after Irradiation in a Murine Tumor Model. Radiation Research, 2006, 165, 326-336.	1.5	58
62	Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer, 2012, 12, 463.	2.6	58
63	Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. Cancer, 2011, 117, 3670-3681.	4.1	57
64	Generation of multicellular tumor spheroids of breast cancer cells: How to go three-dimensional. Analytical Biochemistry, 2013, 437, 17-19.	2.4	57
65	18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) â€" A prospective externally validated study. PLoS ONE, 2018, 13, e0192859.	2.5	57
66	Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes. Radiotherapy and Oncology, 2000, 57, 21-30.	0.6	56
67	Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiotherapy and Oncology, 2005, 76, 194-199.	0.6	56
68	Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. Radiotherapy and Oncology, 2015, 117, 49-54.	0.6	55
69	Learning from scanners: Bias reduction and feature correction in radiomics. Clinical and Translational Radiation Oncology, 2019, 19, 33-38.	1.7	54
70	Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a headâ€andâ€neck squamous cell carcinoma model. International Journal of Cancer, 2011, 129, 870-878.	5.1	53
71	Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?. Radiotherapy and Oncology, 2009, 92, 429-436.	0.6	50
72	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta OncolÃ³gica, 2013, 52, 1257-1271.	1.8	50

#	Article	IF	Citations
73	Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiotherapy and Oncology, 2013, 109, 100-106.	0.6	50
74	Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence. Radiotherapy and Oncology, 2019, 136, 78-85.	0.6	48
75	Therapeutic targeting of autophagy in cancer. Part I: Molecular pathways controlling autophagy. Seminars in Cancer Biology, 2015, 31, 89-98.	9.6	47
76	Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiotherapy and Oncology, 2007, 82, 10-17.	0.6	46
77	The role of 18F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2037-2047.	6.4	45
78	The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia. Radiotherapy and Oncology, 2013, 108, 529-534.	0.6	44
79	HPV, hypoxia and radiation response in head and neck cancer. British Journal of Radiology, 2019, 92, 20180047.	2.2	44
80	Targeting Oxidative Phosphorylation to Increase the Efficacy of Radio- and Immune-Combination Therapy. Clinical Cancer Research, 2021, 27, 2970-2978.	7.0	44
81	Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer. Clinical Cancer Research, 2014, 20, 1345-1354.	7.0	43
82	Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment. Radiotherapy and Oncology, 2013, 108, 17-23.	0.6	42
83	Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiotherapy and Oncology, 2013, 108, 517-522.	0.6	42
84	Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and ^{111}In-Labeled Cetuximab-F(ab′)$_2$. Journal of Nuclear Medicine, 2013, 54, 2118-2124.	5.0	42
85	Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treatment Reviews, 2014, 40, 1182-1191.	7.7	39
86	EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. Radiotherapy and Oncology, 2013, 108, 479-483.	0.6	38
87	EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition. Autophagy, 2018, 14, 283-295.	9.1	38
88	Undertreatment of Tracheal Carcinoma: Multidisciplinary Audit of Epidemiologic Data. Annals of Surgical Oncology, 2009, 16, 246-253.	1.5	37
89	TRIB3 protein denotes a good prognosis in breast cancer patients and is associated with hypoxia sensitivity. Radiotherapy and Oncology, 2011, 101, 198-202.	0.6	37
90	Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas. International Journal of Radiation Oncology Biology Physics, 2019, 105, 548-558.	0.8	37

#	Article	IF	Citations
91	Distributed radiomics as a signature validation study using the Personal Health Train infrastructure. Scientific Data, 2019, 6, 218.	5.3	37
92	A systematic review and quality of reporting checklist for repeatability and reproducibility of radiomic features. Physics and Imaging in Radiation Oncology, 2021, 20, 69-75.	2.9	37
93	64Cu-ATSM and 18FDG PET uptake and 64Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiation Oncology, 2012, 7, 89.	2.7	36
94	Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiotherapy and Oncology, 2013, 106, 383-389.	0.6	36
95	Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment. Cellular Immunology, 2021, 362, 104298.	3.0	35
96	Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. Radiation Oncology, 2012, 7, 150.	2.7	33
97	Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. Lung Cancer, 2018, 126, 32-40.	2.0	33
98	Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. Clinical Cancer Research, 2003, 9, 6363-70.	7.0	32
99	Individualized Dose Prescription for Hypofractionation in Advanced Non-Small-Cell Lung Cancer Radiotherapy: An in silico Trial. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1596-1602.	0.8	31
100	Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 915-924.	6.4	31
101	Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT. Radiotherapy and Oncology, 2017, 122, 295-299.	0.6	31
102	Effects of nicotinamide and carbogen in different murine colon carcinomas: Immunohistochemical analysis of vascular architecture and microenvironmental parameters. International Journal of Radiation Oncology Biology Physics, 2004, 60, 310-321.	0.8	30
103	Irradiation combined with SU5416: Microvascular changes and growth delay in a human xenograft glioblastoma tumor line. International Journal of Radiation Oncology Biology Physics, 2005, 61, 529-534.	0.8	30
104	αB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. BMC Cancer, 2013, 13, 128.	2.6	30
105	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. Cancer Immunology Research, 2019, 7, 150-161.	3.4	29
106	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	2.6	29
107	Effect of cetuximab and fractionated irradiation on tumour micro-environment. Radiotherapy and Oncology, 2010, 97, 322-329.	0.6	28
108	Regulation of TRIB3 mRNA and Protein in Breast Cancer. PLoS ONE, 2012, 7, e49439.	2.5	28

#	Article	IF	Citations
109	Hypoxic regulation of the PERK/ATF4/LAMP3â€arm of the unfolded protein response in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 896-905.	2.0	28
110	GABARAPL1 is required for increased EGFR membrane expression during hypoxia. Radiotherapy and Oncology, 2015, 116, 417-422.	0.6	28
111	Clinical Outcome and Tumour Microenvironmental Effects of Accelerated Radiotherapy with Carbogen and Nicotinamide. Acta OncolÃ³gica, 1999, 38, 875-882.	1.8	27
112	Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging. Clinical Cancer Research, 2012, 18, 6469-6477.	7.0	27
113	Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial. European Journal of Cancer, 2013, 49, 3202-3209.	2.8	27
114	PET of EGFR with ^{64}Cuâ€etuximabâ€F(abâ€²)$_2$ in mice with head and neck squamous cell carcinoma xenografts. Contrast Media and Molecular Imaging, 2016, 11, 65-70.	0.8	26
115	Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer. Radiation Oncology, 2012, 7, 75.	2.7	25
116	Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. Molecular Cancer, 2013, 12, 133.	19.2	25
117	PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging. Clinical Cancer Research, 2015, 21, 3602-3609.	7.0	25
118	Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies. Future Science OA, 2016, 2, FSO84.	1.9	25
119	Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2011, 101, 165-170.	0.6	24
120	Expression of EGFR Under Tumor Hypoxia: Identification of a Subpopulation of Tumor Cells Responsible for Aggressiveness and Treatment Resistance. International Journal of Radiation Oncology Biology Physics, 2012, 84, 807-814.	0.8	24
121	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1858-1867.	6.4	24
122	Imaging Integrin Î±$_v$Î²$_3$ on Blood Vessels with ^{111}In-RGD$_2$ in Head and Neck Tumor Xenografts. Journal of Nuclear Medicine, 2014, 55, 281-286.	5.0	24
123	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. Acta OncolÃ³gica, 2019, 58, 1378-1385.	1.8	24
124	Histopathologic Validation of 3â€²-Deoxy-3â€²-^{18}F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity. Journal of Nuclear Medicine, 2010, 51, 713-719.	5.0	23
125	Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 29.	3.9	23
126	CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. Scientific Reports, 2019, 9, 18898.	3.3	22

#	Article	IF	Citations
127	Deregulation of cap-dependent mRNA translation increases tumour radiosensitivity through reduction of the hypoxic fraction. Radiotherapy and Oncology, 2011, 99, 385-391.	0.6	21
128	Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers. Cellular Oncology (Dordrecht), 2011, 34, 119-129.	4.4	21
129	ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker. Cancers, 2019, 11, 1971.	3.7	21
130	Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine, 2015, 21, 314-321.	2.6	20
131	^{111}In-Cetuximab-F(ab$'$)$_2$ SPECT and ^{18}F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model. Journal of Nuclear Medicine, 2015, 56, 287-292.	5.0	20
132	Adverse effect of smoking on prognosis in human papillomavirus–associated oropharyngeal carcinoma. Head and Neck, 2016, 38, 1780-1787.	2.0	20
133	Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes. Thoracic Cancer, 2019, 10, 2289-2299.	1.9	20
134	Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models. Molecular Pharmaceutics, 2019, 16, 701-708.	4.6	20
135	Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiotherapy and Oncology, 2002, 63, 285-291.	0.6	19
136	Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer, 2014, 14, 130.	2.6	19
137	Tumor Microenvironmental Changes Induced by the Sulfamate Carbonic Anhydrase IX Inhibitor S4 in a Laryngeal Tumor Model. PLoS ONE, 2014, 9, e108068.	2.5	18
138	Prognostic value of the proliferation marker Ki–67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial. Head and Neck, 2015, 37, 171-176.	2.0	18
139	Patterns of proliferation related to vasculature in human head-and-neck carcinomas before and after transplantation in nude mice. International Journal of Radiation Oncology Biology Physics, 2001, 51, 1346-1353.	0.8	17
140	111In-cetuximab-F(ab$'$)2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts. Radiotherapy and Oncology, 2013, 108, 484-488.	0.6	17
141	Effect of hypoxia on the expression of αB-crystallin in head and neck squamous cell carcinoma. BMC Cancer, 2014, 14, 252.	2.6	17
142	Poor prognosis of constitutive γ-H2AX expressing triple-negative breast cancers is associated with telomere length. Biomarkers in Medicine, 2015, 9, 383-390.	1.4	17
143	Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. Radiotherapy and Oncology, 2016, 119, 473-479.	0.6	17
144	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non–Small Cell Lung Cancer by Using Dynamic ^{18}F Fluorodeoxyglucose PET. Radiology, 2017, 283, 547-559.	7.3	16

#	Article	IF	Citations
145	Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 434-441.	0.8	16
146	Thymidine analogues to assess microperfusion in human tumors. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1169-1175.	0.8	14
147	Concurrent celecoxib versus placebo in patients with stage II–III non-small cell lung cancer: A randomised phase II trial. Radiotherapy and Oncology, 2007, 84, 23-25.	0.6	14
148	Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors. Clinical Cancer Research, 2010, 16, 3639-3647.	7.0	14
149	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. Scientific Reports, 2019, 9, 14907.	3.3	14
150	Deep learning model for automatic contouring of cardiovascular substructures on radiotherapy planning CT images: Dosimetric validation and reader study based clinical acceptability testing. Radiotherapy and Oncology, 2021, 165, 52-59.	0.6	14
151	Secretion of pro‐angiogenic extracellular vesicles during hypoxia is dependent on the autophagy‐related protein GABARAPL1. Journal of Extracellular Vesicles, 2021, 10, e12166.	12.2	14
152	The Predictive Value of Early In-Treatment ^{18}F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 1243-1248.	5.0	13
153	Preclinical validation of 111 In-girentuximab-F(ab′²) 2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts. Radiotherapy and Oncology, 2017, 124, 521-525.	0.6	13
154	Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO *in silico* study. British Journal of Radiology, 2020, 93, 20190879.	2.2	13
155	Role of FDG-PET in the diagnosis and management of lung cancer. Expert Review of Anticancer Therapy, 2004, 4, 561-567.	2.4	12
156	Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI. Cancer Research, 2018, 78, 1561-1570.	0.9	12
157	Adding the temporal domain to PET radiomic features. PLoS ONE, 2020, 15, e0239438.	2.5	12
158	Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer. Oncology Research, 2020, 28, 33-40.	1.5	12
159	Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment. Clinical Cancer Research, 2022, 28, 3652-3657.	7.0	12
160	Effect of Carbogen Breathing on the Radiation Response of a Human Glioblastoma Xenograft. Strahlentherapie Und Onkologie, 2006, 182, 408-414.	2.0	11
161	18F-FDG and 18F-FLT Do Not Discriminate Between Reactive and Metastatic Lymph Nodes in Oral Cancer. Journal of Nuclear Medicine, 2009, 50, 490-491.	5.0	11
162	Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer. International Journal of Biological Markers, 2013, 28, 151-160.	1.8	11

#	Article	IF	Citations
163	Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab')₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model. Journal of Nuclear Medicine, 2014, 55, 1665-1670.	5.0	11
164	Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?. Lung Cancer, 2016, 101, 68-75.	2.0	11
165	Stereotactic versus conventional radiotherapy for pain reduction and quality of life in spinal metastases: study protocol for a randomized controlled trial. Trials, 2016, 17, 61.	1.6	11
166	ATG12 deficiency results in intracellular glutamine depletion, abrogation of tumor hypoxia and a favorable prognosis in cancer. Autophagy, 2022, 18, 1898-1914.	9.1	11
167	Esophageal wall dose-surface maps do not improve the predictive performance of a multivariable NTCP model for acute esophageal toxicity in advanced stage NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. Physics in Medicine and Biology, 2017, 62, 3668-3681.	3.0	10
168	Comparison of dose metrics between automated and manual radiotherapy planning for advanced stage non-small cell lung cancer with volumetric modulated arc therapy. Physics and Imaging in Radiation Oncology, 2019, 9, 92-96.	2.9	10
169	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer, 2019, 120, 1037-1044.	6.4	10
170	Deletion of hematopoietic Dectin-2 or CARD9 does not protect against atherosclerotic plaque formation in hyperlipidemic mice. Scientific Reports, 2019, 9, 4337.	3.3	10
171	Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors. Translational Oncology, 2013, 6, 413-419.	3.7	9
172	Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: Correlation between primary and xenograft tumors. Head and Neck, 2013, 36, n/a-n/a.	2.0	9
173	The potential of hyperpolarized ¹³C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents. Acta Oncológica, 2017, 56, 1626-1633.	1.8	9
174	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 147, 227-228.	0.6	9
175	The Effect of Carbogen Breathing and Nicotinamide Added to Standard (Chemo)Radiation Treatment of Advanced Cervical Cancer in Indonesia. International Journal of Gynecological Cancer, 2014, 24, 1628-1635.	2.5	8
176	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. Radiotherapy and Oncology, 2018, 129, 249-256.	0.6	8
177	The Role of Hypoxia and the Immune System in Tumor Radioresistance. Cancers, 2019, 11, 1555.	3.7	8
178	Evaluating the use of optimally respiratory gated 18F-FDG-PET in target volume delineation and its influence on radiation doses to the organs at risk in non-small-cell lung cancer patients. Nuclear Medicine Communications, 2016, 37, 66-73.	1.1	8
179	A practical approach to assess clinical planning tradeoffs in the design of individualized IMRT treatment plans. Radiotherapy and Oncology, 2010, 97, 561-566.	0.6	7
180	Epidermal growth factor receptor imaging in human head and neck cancer xenografts. Acta Oncológica, 2015, 54, 1263-1267.	1.8	7

#	Article	IF	Citations
181	AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC. Radiotherapy and Oncology, 2020, 149, 1-7.	0.6	7
182	Low Phosphorylated AKT Expression in Laryngeal Cancer: Indications for a Higher Metastatic Risk. International Journal of Radiation Oncology Biology Physics, 2013, 87, 349-355.	0.8	6
183	Deletion of haematopoietic Dectin-2 or CARD9 does not protect from atherosclerosis development under hyperglycaemic conditions. Diabetes and Vascular Disease Research, 2020, 17, 147916411989214.	2.0	6
184	The Influence of the Exclusion of Central Necrosis on [18F]FDG PET Radiomic Analysis. Diagnostics, 2021, 11, 1296.	2.6	6
185	Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 369-384.	0.7	6
186	Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells. Molecular Pharmaceutics, 2022, 19, 3511-3520.	4.6	6
187	Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2013, 18, 988-996.	2.2	5
188	α±B-Crystallin Expression is Correlated with Phospho-ERK1/2 Expression in Human Breast Cancer. International Journal of Biological Markers, 2013, 28, 365-370.	1.8	5
189	γ3-H2AX Foci in Peripheral Blood Lymphocytes to Quantify Radiation-Induced DNA Damage After 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2015, 56, 501-502.	5.0	5
190	Radiation Promptly Alters Cancer Live Cell Metabolic Fluxes: An In Vitro Demonstration. Radiation Research, 2016, 185, 496.	1.5	5
191	Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. Cancers, 2021, 13, 1069.	3.7	5
192	Radiomics integration into a picture archiving and communication system. Physics and Imaging in Radiation Oncology, 2021, 20, 30-33.	2.9	5
193	PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases. Frontiers in Immunology, 2022, 13, 837370.	4.8	5
194	Toll-like receptor 4 in bone marrow-derived cells as well as tissue-resident cells participate in aggravating autoimmune destructive arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1407-1415.	0.9	4
195	Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT. Physics and Imaging in Radiation Oncology, 2018, 7, 16-22.	2.9	4
196	EBUS and EUS guided fine needle aspirations for molecular diagnostic analysis in lung cancer. Thoracic Cancer, 2012, 3, 201-206.	1.9	3
197	Downregulation of matrix Gla protein is a biomarker for tamoxifen-resistant and radioresistant breast cancer. Biomarkers in Medicine, 2019, 13, 841-850.	1.4	3
198	National societies' needs as assessed by the ESTRO National Societies Committee survey: A European perspective. Radiotherapy and Oncology, 2020, 151, 176-181.	0.6	3

#	Article	IF	Citations
199	Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome: In Regard to Evans et al. (Int J Radiat Oncol Biol Phys 2007;69:1024â€"1031). International Journal of Radiation Oncology Biology Physics, 2008, 70, 1616.	0.8	2
200	Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by ¹⁸F-FAZA and ¹²⁵I-Gluco-RGD Autoradiography. Journal of Nuclear Medicine, 2008, 49, 1732.1-1732.	5.0	2
201	Engineered microparticles delivering oxygen to enhance radiotherapy efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8009-E8009.	7.1	2
202	Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models. Physics and Imaging in Radiation Oncology, 2021, 19, 145-150.	2.9	2
203	Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy. Frontiers in Oncology, 2021, 11, 786089.	2.8	2
204	Radiation-induced rib fractures after stereotactic body radiation therapy: Predict to prevent?. Radiotherapy and Oncology, 2017, 123, 173-175.	0.6	1
205	Letter to the editor: Hypoxia kinetics and histology in combined radiotherapy and oxidative phosphorylation inhibition effects on antitumor immunity. , 2021, 9, e001793.		1
206	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.. Journal of Clinical Oncology, 2012, 30, e13111-e13111.	1.6	1
207	Correlation of Segmented Metabolic Tumor Volume with Outcome - Letter. Clinical Cancer Research, 2010, 16, 1968-1968.	7.0	0
208	Balancing Radiation Pneumonitis Versus Locoregional Tumor Control in Nonâ€"Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, e35-e36.	1.1	0
209	Balancing Radiation Pneumonitis Versus Locoregional Tumor Control in Nonâ€"Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, e47.	1.1	0
210	In-treatment assessment of response in locally advanced NSCLC: Paving the way for personalized medicine. Lung Cancer, 2014, 86, 374.	2.0	0
211	In response to â€œHistopathologic validation of 3â€²-deoxy-3â€²-18F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude miceâ€• Radiotherapy and Oncology, 2015, 114, 417-418.	0.6	0
212	Segmentation Uncertainty Estimation as a Sanity Check for Image Biomarker Studies. Cancers, 2022, 14, 1288.	3.7	0
213	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
214	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
215	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0
216	Adding the temporal domain to PET radiomic features. , 2020, 15, e0239438.		0